

WORLD INTELLECTUAL PROPERTY ORGANIZATIO International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

INTERNATIONAL AFFEIGATION TODAY	T	7/0 00/11550
(51) International Patent Classification 5:		(11) International Publication Number: WO 93/11773
A61K 31/57 // (A61K 31/57 A61K 31:165)	A1	(43) International Publication Date: 24 June 1993 (24.06.93)
(21) International Application Number: PCT/El (22) International Filing Date: 7 December 1992		DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG,
(30) Priority data: 91311761.0 18 December 1991 (18.1	2.91)	BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG). Published
(71) Applicant: AKTIEBOLAGET ASTRA [SE/SE] Södertälje (SE).		With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of
(72) Inventors: CARLING, Christer, Carl, Gustav; 8, S-240 10 Dalby (SE). TROFAST, Jan, Wilpenkroken 34, S-226 47 Lund (SE).	lliam ;	Va-
(74) Agents: HJERTMAN, Ivan et al.; AB Astra, I partment, S-151 85 Södertälje (SE).	Patent 1	De-
(54) Title: NEW COMBINATION OF FORMOTE	ROL A	AND BUDESONIDE
(57) Abstract Effective amounts of formoterol (and/or a phy in combination for simultaneous, sequential or sepa	ysiologi rate adı	cally acceptable salt and/or solvate thereof) and budesonide are used ministration by inhalation in the treatment of respiratory disorder.
·		
		·

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

				140	Mauritania
AT	Austria	FR	France	MR	
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinca	NO	Norway
		GR	Greece	NZ	New Zealand
BF	Burkina Faso	HU	Hungary	PL	Poland
BG	Bulgaria	IE	treland	PT	Portugal
BJ	Benin			RO	Romania
BR	Brazil	IT	Italy	RU	Russian Federation
CA	Conada	JP	Japan	SD	Sudan
CF	Central African Republic	КP	Democratic People's Republic		Sweden
CC	Congo		of Korea	SE	Slovak Republic
CH	Switzerland	KR	Republic of Korea	SK	•
Ci	Côte d'Ivoire	KZ	Kazaklistan	SN	Scregal
CM	Cameroon	LI	Licehtenstein	รบ	Soviet Union
CS.	Czechoslovakia -	LK	Sri Lanka	TD	(.had
	Czech Republic	I.U	Luxembourg	TG	Togo
cz	•	MC	Monaco	UA	Ukraine
DE	Germany	MC	Madagascar	us	United States of America
DK	Denmark	_	Mali	VN	Vict Nam
ES	Spain	Ml.			
FI	Finland	MN	Mongolia		

New combination of formoterol and budesonide.

5

10


15

Field of the invention

This invention relates to improvements in the treatment of mild as well as severe asthma and other respiratory disorders. More particularly, it relates to the use of a bronchodilator in combination with a steroidal anti-inflammatory drug for the treatment of respiratory disorders such as asthma, and to pharmaceutical compositions containing the two active ingredients. It emphasizes the use of a long-acting bronchodilator which provides rapid relief of symptoms.

Background of the invention

20 .There have recently been significant advances in our understanding of asthma. Despite many advances, both in awareness of the disease by doctors and patients alike, coupled with the introdction of very powerful and effective anti-asthma drugs, asthma remains a poorly 25 understood and often poorly treated disease. Previously, contraction of airway smooth muscles has been regarded as the most important feature of asthma. Recently there has been a marked change in the way asthma is managed, stemming from the fact that asthma is recognized as a chronic inflammatory disease. Uncontrolled airway 30 inflammation may lead to mucosal damage and structural changes giving irrversible narrowing of the airways and fibrosis of the lung tissue. Therapy should therefore be aimed at controlling symptoms so that normal life is 35 possible and at the same time provide basis for treating



10

the underlying inflammation.


The most common cause for poor control of asthma is poor compliance with the long-term management of chronic asthma, particularly with prophylatic treatments, such as inhaled steroids, which do not give immediate symptom relief. Patients will readily take β_2 -agonist inhalers, since these provide rapid relief of symptoms, but often do not take prophylactic therapy, such as inhaled steroids, regularly because there is no immediate symptomatic benefit. They also counteract down regulation of β_2 -adrenoceptor agonists.

methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl] 15 formamide), is an adrenoceptor agonist which selectively stimulates β_2 -receptors, thus producing relaxation of bronchial smooth muscle, inhibition of the release of endogenous spasmogens, inhibition of oedema caused by endogenous mediators, and increased mucociliary 20 clearence. Inhaled formoterol fumarate acts rapidly, usually within minutes which gives the patient immediate confirmation that he has taken an adequat dose and thereby avoiding overdosing of both β -agonist and steroid. Inhaled formoterol also exerts a prolonged 25 bronchodilation, which in clinical trials has been demonstrated as up to 12 hours.

Budesonide, (16,17-butylidenebis(oxy)-11,21
30 dihydroxypregna-1,4-diene-3,20-dione), may be given in a high inhaled dose (up to 2 mg daily) with very low systemic effects, possibly because of its rapid metabolism. The high rapid systemic elimination of budesonide is due to extensive and rapid hepatic

35 metabolism. Long term clinical studies have shown that inhaled budesonide is a pharmacologically safe drug. High doses of inhaled budesonide are highly effective and well

3.5



5 The inhaled route of administration enables the dose to be delivered directly to the airways. By this type of administration, it is possible to give a small dose and thereby minimizing unwanted side-effects. The drawbacks of the currently available bronchodilators are their relatively short duration of action. By using a compound with long duration e.g. formoterol it would be possible to avoid the nocturnal asthma, which so often causes considerable anxiety and debility to the patients. Formoterol gives less nocturnal waking than the commonly used short-acting agonists like salbutamol, terbutaline and the like. Formoterol has been registered for oral administration in Japan since 1986.

Pharmaceutical combinations of long-acting β_2 -agonists and steroids are disclosed in two European applications, EP 416950 which discloses the combination of salmeterol and beclomethasone, and EP 416951 which discloses the combination of salmeterol and fluticasone propionate.

In Ann. Allergy 1989, 63 (3), p. 220-224 the use of a β₂-agonist, i.e. formoterol and a steroid, i.e. budesonide seperately are mentioned. It is not disclosed a pharmaceutical combination including both formoterol and budesonide, or the use of the two compounds in
combination therapy. The use of a β₂-agonist and a

combination therapy. The use of a β_2 -agonist and a steroid separately is also mentoined in Lung (1990), 168, no. supp, p. 105-110.

Outline of the Invention

The present invention is based on the concept of a novel combination therapy whereby formoterol (and/or a

10

15

20

25


35

physiologically acceptable salt and/or solvate thereof) and budesonide are administrated simultaneously, sequentially or seperately by inhalation. This combination has not only a greater efficiency and duration of bronchodilator action but the combination also has a rapid onset of action. This new feature is of utmost importance in order to establish a higher compliance for patients and it provides a rescue medicine thereby avoiding the necessity for the patient of carrying two different inhalers. This simplifies life for patients considerably and makes life more comfortable and secure. The rapid onset of the long-acting β_2 -agonist gives the patient immediate confirmation that he has taken an adequate dose and thereby avoiding overdosing of both β_2 -agonist and steroid. Since the use of formoterol instead of salmoterol gives a much more rapid onset the combinations according to the invention have a number of advantages compared to the combinations disclosed i EP 416950 and EP 41651. The combination according to present invention permits a twice daily dosing regime as a basic treatment of asthma, particularly nocturnal asthma.

The present invention provides a medicament containing, separately, or together, (i) formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and (ii) budesonide for simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorder.

The invention also provides a pharmaceutical composition for administration by inhalation in the treatment of respiratory disorder which composition comprises formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide.

According to another aspect of the invention there are provided pharmaceutical compositions comprising effective



10

30

amounts of formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide as a combined preparation for simultaneous, sequential or seperate administration by inhalation in the treatment of respiratory disorder.

5

The invention further provides formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide for use in combination therapy by simultaneous, sequential or seperate administration by inhalation in the treatment of respiratory disorder.

Further the invention provides the use of formoterol (and/or a physiologically acceptable salt and/or solvate 15 thereof) in the manufacture of a medicament for combination therapy where formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide are administered simultaneously, sequentially or seperately by inhalation in the treatment 20 of respiratory disorder and the use of budesonide in the manufacture of a medicament for combination therapy where formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide are administered simultaneously, sequentially or separately by inhalation 25 in the treatment of respiratory disorder.

The invention additionally relates to the use of formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide in the manufacture of a medicament for combination therapy for simultaneous, sequential or seperate administration of formoterol and budesonide by inhalation in the treatment of respiratory disorder.

35 According to a further feature of the invention there is provided a method of treating respiratory disorder which comprises the simultaneous, sequential or separate

administration by inhalation of effective amounts of formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide.

Suitable physiologically salts of formoterol include acid addition salts derived from inorganic and organic acids, such as the hydrochloride, hydrobromide, sulphate, phosphate, maleate, fumarate, tartrate, citrate, benzoate, 4-methoxybenzoate, 2- or 4- hydroxybenzoate, 4-chlorobenzoate, p-toluenesulphonate, methanesulphonate, ascorbate, salicylate, acetate succinate, lactate, glutarate, gluconate, tricarballylate, hydroxynaphthalenecarboxylate or oleate. Formoterol is preferably used in the form of its fumarate salt and as a dihydrate.

The ratio of formoterol to budesonide used according to the invention is preferably within the range of 1:4 to 1:70. The two drugs may be administered separately in the same ratio.

The intended dose regimen is a twice daily administration, where the suitable daily dose of formoterol is in the range of 6 to 100 μ g with a preferred dose of 6-48 μ g and the suitable daily dose for budesonide is 50 to 4800 μ g with a preferred dose of 100-1600 μ g. The particular dose used will strongly depend on the patient (age, weight etc) and the severity of the disease (mild, moderate, severe asthma etc).

30

35

20

25

For administration, the combination is suitably inhaled from a nebulizer, from a pressurized metered dose inhaler or as a dry powder from a dry powder inhaler (e.g. as sold under the trade mark Turbuhaler) or from a dry powder inhaler utilizing gelatine, plastic or other capsules, cartridges or blister packs.

A diluent or carrier, generally non-toxic and chemically inert to the medicament e.g. lactose, dextran, mannitol or glucose or any additives that will give the medicament a desired taste, can be added to the powdered medicament.

5


Examples of the preparation of suitable dosage forms according to the invention include the following:
Formoterol fumarate dihydrate and budesonide (optionally premicronized) are mixed in the proportions given above.
The agglomerated, free-flowing micronized mixture may be

The agglomerated, free-flowing micronized mixture may be filled into dry powder inhaler such as sold under the trade mark Turbuhaler. When a capsule system issued, it is desirable to include a filler in the mixture.

- The micronized mixture may be suspended or dissolved in a liquid propellant mixture which is kept in a container that is sealed with a metering valve and fitted into a plastic actuator. The propellants used may be chlorofluorocarbons of different chemical formulae. The most frequently used chlorofluorocarbon propellants are trichloromonofluoromethane (propellant 11), dichlorodifluoromethane (propellant 12), dichlorotetrafluoroethane (propellant 134a) and 1,1-difuoroethane (propellant 134a) and 1,1-difuoroethane (propellant 152a). Low concentrations of a
- ethane (propellant 152a). Low concentrations of a surfactant such as sorbitan trioleate, lecithin, disodium dioctylsulphosuccinate or oleic acid may also be used to improve the physical stability.
- The invention is further illustrated by way of example with reference to the following Examples.

Example 1 - Dry Powder Inhaler (Turbuhaler)


35	Active ingredient	<u>Per dose</u>
•	Formoterol (as fumarate dihydrate)	12 µg
٠	Budesonide	200 μg



The storage unit of the inhaler is filled with sufficient for at least 200 doses.


5	Active ingredient Formoterol (as fumarate dihydrate) Budesonide The storage unit is filled with sufficient for a 200 doses.	Per dose 24 μg 200 μg t least
10		
	Active ingredient	<u>Per dose</u>
	Formoterol (as fumarate dihydrate)	12 µg
	Budesonide	100 µg
	The storage unit is filled with sufficient for a	t least
15	200 doses.	
	Example 2 - Metered dose inhaler	

	Active ingredient	Per dose
20	Formoterol (as fumarate dihydrate)	12 µg
	Budesonide	200 μg
	Stabilizer	0.1 - 0.7 mg
	Propellant	25 - 100 μl
	-	•
25		
	Active ingredient	<u>Per dose</u>
	Formoterol (as fumarate dihydrate)	24 μg
	Budesonide	200 μg
	Stabilizer	0.1 - 0.7 mg
30	Propellant	25 - 100 μl
	•	
	Active ingredient	Per dose
	Formoterol (as fumarate dihydrate)	12 µg
35	Budesonide	200 µg
	Stabilizer	0.1 - 0.7 mg
	Propellant	25 - 100 μ1
	-	



Example 3 - Metered dose dry powder formulation

	Active ingredient					Per d	<u>ose</u>
	Formoterol (as fumarate dihydrate)					12	μg
5	Budesonide					200	μg
	Lactose	up	to	5,	12.5	or 25	mg
	Active ingredient					Per d	ose
10	Formoterol (as fumarate dihydrate)					24	μg
	Budesonide					200	μg
	Lactose	up	to	5,	12.5	or 25	mg
							•
15	Active ingredient					Per d	ose
	Formoterol (as fumarate dihydrate)		•			12	μg
	Budesonide					100	μg
	Lactose	up	to	5,	12.5	or 25	mg



CLAIMS

- 1. A medicament containing, seperately or together, (i) formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and (ii) budesonide for simultaneous, sequential or seperate administration by inhalation in the treatment of respiratory disorder.
- A pharmaceutical composition for administration by inhalation in the treatment of respiratory disorder which composition comprises formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide.
- 3. A pharmaceutical composition comprising effective amounts of formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide as a combined preparation for simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorder.
- Formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide for use in combination therapy by simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorder.
- 5. The use of formoterol (and/or a physiologically acceptable salt thereof) in the manufacture of a medicament for combination therapy where formoterol (and/or physiologically acceptable salt and/or solvate thereof) and budesonide are administered simultaneously, sequentially or separately by inhalation in the treatment of respiratory disorder.
 - 6. The use of budesonide in the manufacture of a medicament for combination therapy where formoterol

(and/or a physiologically acceptable salt and/or solvate thereof) and budesonide are administered simultaneously, sequentially or separately by inhalation in the treatment of respiratory disorder.

5

10

7. The use of formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide in the manufacture of a medicament for combination therapy for simultaneous, sequential or separate administration of formoterol and budesonide by inhalation in the treatment of respiratory disorder.



L CLASSII	CATION OF SUBJE	CT MATTER (If several classification	symbols apply, indicate all)6	
		Classification (IPC) or to both National		
	. 5 A61K31/5			
II. FIELDS	SEARCHED			
		Minimum Docu	mentation Searched	
Classificati	ion System		Classification Symbols	·
Int.C1	. 5	A61K		
·			er than Minimum Documentation is are Included in the Fields Searched ⁸	
III. DOCUM	MENTS CONSIDERE	D TO BE RELEVANT ⁹		
Category °	Citation of Do	cument, 11 with indication, where approp	riate, of the relevant passages 12	Relevant to Claim No.13
х		OF ALLERGY no. 3, September 198	9,	1-7
	JEÄN H. agonists treatmen cited in see page see page	MARSAC ET AL. 'Inhale and inhaled steroids to fasthma' the application 221, column 2; table 221, column 3, line 23; summary *	in the	
X	pages 10 NILS SVE beta-ago	, no. SUPP, 1990, NEW 5 - 110 DMYR 'The current planists in the managemethe application	ce of	1-7
	٠			
"A" documents of the constant	idered to be of particul er document but publis g date ment which may throw h is cited to establish ti ion or other special rea- ment referring to an or r means ment published prior to than the priority date	ral state of the art which is not ar relevance hed on or after the international doubts on priority claim(s) or he publication date of another son (as specified) ral disclosure, use, exhibition or the international filing date but	"I" later document published after the interna or priority date and not in conflict with the cited to understand the principle or theory invention "X" document of particular relevance; the claim cannot be considered novel or cannot be convolve an inventive step "Y" document of particular relevance; the claim cannot be considered to involve an inventifucument is combined with one or more of ments, such combination being obvious to in the art. "&" document member of the same patent familiar.	e application but runderlying the med invention onsidered to med invention we step when the ther such docu- a person skilled
	ctual Completion of the	- International Seasch	Date of Mailing of this International Searce	h Report
Secon me A	•	IL 1993	28/4/95	ar and and a second
International !	Searching Authority EUROPEAI	N PATENT OFFICE	Signature of Authorized Officer LEHERTE C.F.M.	

Ferm PCT/ISA/210 (second sheet) (Jamesry 1985)

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

□ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
OTHER.

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.